Moxifloxacin
Moxifloxacin, Vigamox (moxifloxacin) is a small molecule pharmaceutical. Moxifloxacin was first approved as Avelox on 1999-12-10. It is used to treat bacterial infections, bacterial pneumonia, bacteroides infections, bronchitis, and cystitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Moxifloxacin, Vigamox (discontinued: Avelox, Moxeza, Moxifloxacin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Moxifloxacin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MOXIFLOXACIN HYDROCHLORIDE | Fresenius Kabi | N-205572 RX | 2015-04-03 | 1 products, RLD, RS |
| VIGAMOX | Harrow | N-021598 RX | 2003-04-15 | 1 products, RLD, RS |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| avelox | New Drug Application | 2011-12-13 |
| avelox abc pack | New Drug Application | 2009-10-25 |
| dex-moxi | unapproved drug other | 2020-02-10 |
| dex-moxi pf | unapproved drug other | 2018-05-08 |
| dex-moxi-ketor | unapproved drug other | 2020-02-10 |
| dexmoxiketor pf | unapproved drug other | 2018-05-08 |
| ixoba m | unapproved drug other | 2021-11-03 |
| moxeza | New Drug Application | 2021-08-11 |
| moxifloxacin | ANDA | 2024-10-09 |
| moxifloxacin hydrochloride | ANDA | 2024-10-04 |
Show 8 more
Indications
FDA
EMA
Show 8 more
Agency Specific
FDA
EMA
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01M: Quinolone antibacterials
— J01MA: Fluoroquinolone antibacterials, systemic
— J01MA14: Moxifloxacin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AE: Fluoroquinolone antiinfectives, ophthalmologic
— S01AE07: Moxifloxacin
Clinical
Clinical Trials
646 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 176 | 1 | — | 4 | 2 | 183 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 7 | 28 | 21 | 6 | 9 | 62 |
| Infections | D007239 | EFO_0000544 | — | 6 | 2 | 14 | 6 | 6 | 34 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 1 | 19 | 17 | 1 | 2 | 33 |
| Pneumonia | D011014 | EFO_0003106 | — | — | 5 | 14 | 5 | 7 | 31 |
| Cataract | D002386 | HP_0000518 | H26.9 | 3 | 3 | 3 | 19 | 4 | 30 |
| Communicable diseases | D003141 | — | — | — | 2 | 13 | 6 | 1 | 22 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | 6 | 8 | 3 | 4 | 16 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 5 | 1 | 4 | 4 | — | 13 |
| Bacterial infections | D001424 | — | A49 | 3 | — | 2 | 5 | 2 | 12 |
Show 69 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 8 | — | 1 | — | 2 | 11 |
| Keratitis | D007634 | HP_0000491 | H16 | — | 1 | 7 | — | 2 | 9 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 2 | 6 | — | — | 8 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 5 | — | 1 | — | — | 6 |
| Community-acquired infections | D017714 | — | — | — | 2 | 4 | — | — | 6 |
| Neoplasms | D009369 | — | C80 | 2 | 1 | 1 | — | 1 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | 3 | — | — | 5 |
| Keratoconus | D007640 | EFO_0004223 | H18.6 | 1 | 1 | 1 | — | 3 | 5 |
| Otitis media | D010033 | EFO_0004992 | H66.9 | — | 1 | 2 | — | 1 | 4 |
| Mycobacterium infections | D009164 | — | A31.9 | 1 | 1 | 3 | — | — | 4 |
Show 62 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 13 | 1 | — | — | — | 14 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 3 | 1 | — | — | — | 4 |
| Pharmacological phenomena | D000069437 | — | — | 2 | 1 | — | — | — | 3 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | 1 | — | — | — | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 1 | — | — | — | 2 |
| Endometriosis | D004715 | EFO_0001065 | N80 | 1 | 1 | — | — | — | 2 |
| Cholangitis | D002761 | HP_0030151 | K83.0 | — | 1 | — | — | — | 1 |
| Amenorrhea | D000568 | — | N91.2 | — | 1 | — | — | — | 1 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | — | 1 | — | — | — | 1 |
| H1n1 subtype influenza a virus | D053118 | — | — | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | 4 | — | — | — | 3 | 7 |
| Hepatitis c | D006526 | — | B19.2 | 6 | — | — | — | — | 6 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 5 | — | — | — | — | 5 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 5 | — | — | — | — | 5 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 5 | — | — | — | — | 5 |
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | — | — | — | — | 4 |
| Asthma | D001249 | EFO_0000270 | J45 | 4 | — | — | — | — | 4 |
| Therapeutic equivalency | D013810 | — | — | 4 | — | — | — | — | 4 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 4 | — | — | — | — | 4 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 3 | — | — | — | — | 3 |
Show 77 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | — | 4 | 4 |
| Pathologic dilatation | D004108 | — | — | — | — | — | — | 3 | 3 |
| Regeneration | D012038 | — | — | — | — | — | — | 3 | 3 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 2 | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 2 | 2 |
| Peritonitis | D010538 | EFO_0008588 | K65 | — | — | — | — | 2 | 2 |
| Pneumococcal pneumonia | D011018 | EFO_1001474 | J13 | — | — | — | — | 1 | 1 |
| Pneumococcal infections | D011008 | EFO_0000772 | J13 | — | — | — | — | 1 | 1 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | — | 1 | 1 |
| Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 1 | 1 |
Show 24 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Moxifloxacin |
| INN | moxifloxacin |
| Description | Moxifloxacin is a quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents. It has a role as an antibacterial drug. It is a quinolinemonocarboxylic acid, a quinolone, a member of cyclopropanes, a pyrrolidinopiperidine, an aromatic ether, a quinolone antibiotic and a fluoroquinolone antibiotic. It is a conjugate base of a moxifloxacinium(1+). |
| Classification | Small molecule |
| Drug class | antibacterials (quinolone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12 |
Identifiers
| PDB | — |
| CAS-ID | 151096-09-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL32 |
| ChEBI ID | 63611 |
| PubChem CID | 152946 |
| DrugBank | DB00218 |
| UNII ID | U188XYD42P (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Moxifloxacin
+
Dexamethasone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Moxifloxacin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 24,027 documents
View more details
Safety
Black-box Warning
Black-box warning for: Avelox, Avelox abc pack, Moxifloxacin, Moxifloxacin hydrochloride, Moxifloxacin hydrochloride tablets, 400 mg, Trimipramine maleate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
29,390 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use